Literature DB >> 21819751

Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.

Peter K Smith1, Joel Collins.   

Abstract

BACKGROUND: Vasomotor rhinitis (VMR) is a hypersensitivity syndrome with heightened reactivity to environmental triggers.
METHODS: Twenty-two patients with severe VMR were treated nasally with either normal saline or 0.6% olopatadine and challenged nasally with a hyperosmolar mannitol solution.
RESULTS: Treatment with 0.6% olopatadine resulted in an improvement in instantaneous nasal symptom scores at 5 and 30 minutes (p < 0.01) compared with baseline and at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). There was also an improvement in nasal peak inspiratory flow rate at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01).
CONCLUSION: In this patient population 0.6% olopatadine appears to be efficacious in symptom reduction in VMR and protects from hyperosmolar challenge.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21819751     DOI: 10.2500/ajra.2011.25.3620

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  4 in total

Review 1.  Nonallergic rhinitis.

Authors:  Phil Lieberman; Debendra Pattanaik
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

2.  Clinical effect of pricking blood at neiyingxiang (ExHN 9) on non-allergic rhinopathy: study protocol for a randomized controlled trial.

Authors:  Kyu Seok Kim; Sang Gyu Go; Yoon-Bum Kim
Journal:  Trials       Date:  2012-04-16       Impact factor: 2.279

3.  The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions.

Authors:  Desiderio Passali; Cemal Cingi; Paola Staffa; Francesco Passali; Nuray Bayar Muluk; Maria Luisa Bellussi
Journal:  Asia Pac Allergy       Date:  2018-01-25

Review 4.  Itch Beyond the Skin-Mucosal Itch.

Authors:  Olivia J Ly Lesslar; Peter K Smith
Journal:  Front Allergy       Date:  2021-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.